WASHINGTON -- The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 ...

A new study published in the journal Nature Medicine suggests that GLP-1 medications such as Ozempic and Wegovy could have a host of other potential benefits beyond treating obesity, including a ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...